NanoViricides reports $4.97M cash, $7.5M net assets, but lacks funding to operate beyond September 2025.

NanoViricides, Inc. reported its fiscal results for the year ending June 30, 2024, showing $4.97 million in cash and $7.5 million in net assets. The company utilized $6.31 million in operating cash, primarily for clinical trials of its antiviral drug NV-387. Despite progress in trials, including safety in Phase Ia/Ib and effectiveness against multiple viruses, NanoViricides lacks sufficient funding to operate through September 2025 and is seeking alternative financing options.

September 30, 2024
5 Articles